Welcome to LookChem.com Sign In|Join Free

CAS

  • or

133766-36-6

133766-36-6

Post Buying Request

133766-36-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

133766-36-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 133766-36-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,7,6 and 6 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 133766-36:
(8*1)+(7*3)+(6*3)+(5*7)+(4*6)+(3*6)+(2*3)+(1*6)=136
136 % 10 = 6
So 133766-36-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H15BrN2O2/c1-2-18-13(17)11(15)5-8-7-16-12-4-3-9(14)6-10(8)12/h3-4,6-7,11,16H,2,5,15H2,1H3

133766-36-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl (2S)-2-amino-3-(5-bromo-1H-indol-3-yl)propanoate

1.2 Other means of identification

Product number -
Other names 5-Bromotryptophan ethyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:133766-36-6 SDS

133766-36-6Upstream product

133766-36-6Downstream Products

133766-36-6Relevant articles and documents

TETRA-CYCLIC CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS

-

Page/Page column 44, (2008/06/13)

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 133766-36-6